Advances in Myeloma, Leukemia & Lymphoma Highlighted

Carfilzomib emerges as a potential treatment option for myeloma

The proteasome inhibitors are a favorite of mine because they target a very interesting complex of proteins inside cells that was discovered in the 1990s. Two phase 2 trials have been conducted to study the efficacy of the proteasome inhibitor carfilzomib in treatment of refractory or resistant myeloma. [MORE]

Studies highlight progress in lymphoma, pose more questions

I finally got to blog on what is news at this year's ASH meeting in San Diego. More than 1,000 studies were presented on hematologic malignancies and benign hematologic disorders. But for lymphoma, I think the most important studies are the following three. [MORE]

Highlights From the 2011 American Society of Hematology Meeting

Different Dosing Schedule May Revive Withdrawn Drug

A drug removed from the market last year may have a second chance after researchers tweaked the dose for older patients with acute myeloid leukemia. [MORE]

New Lymphoma Therapy Adcetris Tested in Newly Diagnosed Patients

With the August approval of Adcetris for Hodgkin lymphoma patients who have relapsed after stem cell transplantation or two lines of chemotherapy, researchers are now examining whether the drug will help newly diagnosed patients. [MORE]

GA101 Could Upstage Rituxan in Lymphoma

GA101, an investigational cancer therapy that targets the CD20 receptor found on non-Hodgkin lymphoma cells, could be the next step for patients who relapse on Rituxan, a current standard of therapy. [MORE]

Investigational Drug Shows Benefit in CLL

Researchers are testing a new targeted therapy that blocks a B-cell signaling pathway, specifically the Bruton's tyrosine kinase (BTK), which is responsible for normal B-cell development. When that signaling goes awry, such as BTK getting stuck in the "on" position, non-Hodgkin lymphoma cells can develop and multiply. [MORE]

No Need for Maintenance Rituxan in Asymptomatic Follicular Lymphoma

Patients who are not suffering from symptoms of nonbulky follicular lymphoma are better off waiting until symptoms occur before beginning chemotherapy instead of undergoing maintenance Rituxan (rituximab) to delay therapy, scientists reported at the annual meeting of the American Society of Hematology. [MORE]

Ponatinib Overcomes Tricky Mutation in CML

The PACE trial, which is studying a novel drug called ponatinib that targets the BCR-ABL mutation, found that the drug overcomes a mutation that has been resistant to all previous approved therapies. [MORE]

More News

• Late effects of stem cell transplant common and often debilitating
• New antibody shows promise in relapsed non-Hodgkin lymphoma
• Chemo alone trumps chemo plus radiation for early-stage Hodgkin lymphoma
• Jakafi (ruxolitinib) boosts myelofibrosis survival
• Leukemia drug pulled from U.S. sparks new interest
• Most new myeloma patients respond to carfilzomib in phase 2 trial
• Ponatinib helps refractory leukemia in nearly half of patients

Become a fan of CURE on Facebook.

Follow CURE on Twitter.

Send feedback to editor@curetoday.com.

Sign up for our email newsletters, which you can now personalize by tumor type, survivorship or caregiver status.

This email was sent to you because you have provided your email address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add enews@curetoday.com to your address book or safe sender list to ensure this email is delivered to your inbox.

© 2012 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic or treatment advice.